EcoR1 Capital LLC Invests $7.02 Million in Zura Bio Limited $ZURA

EcoR1 Capital LLC acquired a new stake in shares of Zura Bio Limited (NASDAQ:ZURA) during the first quarter, HoldingsChannel.com reports. The institutional investor acquired 1,179,715 shares of the company’s stock, valued at approximately $7,019,000. Zura Bio accounts for approximately 0.3% of EcoR1 Capital LLC’s investment portfolio, making the stock its 21st biggest position.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZURA. Allworth Financial LP bought a new position in Zura Bio in the fourth quarter worth about $30,000. Scientech Research LLC bought a new stake in shares of Zura Bio in the 3rd quarter valued at about $45,000. Dimensional Fund Advisors LP bought a new stake in shares of Zura Bio in the 4th quarter valued at about $123,000. Squarepoint Ops LLC purchased a new position in shares of Zura Bio in the 3rd quarter worth approximately $109,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Zura Bio in the 3rd quarter worth approximately $138,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on ZURA shares. Wall Street Zen cut shares of Zura Bio from a “sell” rating to a “strong sell” rating in a research report on Sunday, July 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Wedbush reaffirmed an “outperform” rating and set a $15.00 price target on shares of Zura Bio in a research report on Wednesday, July 1st. Finally, William Blair began coverage on Zura Bio in a report on Wednesday, July 8th. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Zura Bio Stock Up 2.9%

ZURA opened at $5.38 on Tuesday. The company has a market cap of $510.45 million, a P/E ratio of -4.94 and a beta of -0.03. The firm’s 50-day moving average price is $4.57 and its 200-day moving average price is $5.38. Zura Bio Limited has a 52-week low of $1.35 and a 52-week high of $7.44.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, May 7th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). On average, research analysts anticipate that Zura Bio Limited will post -0.76 EPS for the current fiscal year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.